All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

MDS Hub

MDS Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
SubtypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2023-02-10T10:37:56.000Z

What do the ELM-2 results tell us about the efficacy of odronextamab for R/R DLBCL?

By Abhilasha Verma, Kreena Mistry
Featured
Won Kim
Feb 10, 2023
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in lymphoma.

Bookmark this article

During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub was pleased to speak with Won Seog Kim, Sungkyunkwan University, Seoul, KR. We asked, What do the ELM-2 results tell us about the efficacy of odronextamab for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)?

What do the ELM-2 results tell us about the efficacy of odronextamab for R/R DLBCL?

Kim discusses results from the DLBCL cohort of the prospective phase II ELM-2 trial (NCT03888105) of odronextamab, which incorporated an optimized step-up regimen. He then highlights the promising efficacy and manageable toxicity profile of odronextamab in patients with R/R DLBCL.

More about...
Aggressive B-cell lymphomasASH 2022Diffuse large B-cell lymphomaOdronextamab

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Related articles

Add bookmark

FDA lifts partial clinical hold on odronextamab trials in B-cell non-Hodgkin lymphomas

On December 14, 2020, it was reported that the U.S. Food and Drug Administration (FDA) placed a partial clinical hold on trials of odronextamab in B-cell...

May 20, 2021
Add bookmark

FDA lifts partial clinical hold on odronextamab trials in B-cell non-Hodgkin lymphomas

On December 14, 2020, it was reported that the U.S. Food and Drug Administration (FDA) placed a partial clinical...

May 20, 2021
Add bookmark

Using ctDNA analysis in risk profiling of frontline DLBCL: Results from the POLARIX study

In the risk profiling of previously untreated patients with DLBCL from the POLARIX study using ctDNA, results suggested that ctDNA analysis has prognostic...

Jan 27, 2023
Add bookmark

Using ctDNA analysis in risk profiling of frontline DLBCL: Results from the POLARIX study

In the risk profiling of previously untreated patients with DLBCL from the POLARIX study using ctDNA, results...

Jan 27, 2023

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox